Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies Clearing Cell And Gene Therapy Manufacturing Hurdles

This article was originally published in Scrip

Executive Summary

The promise of cell and gene therapies is great, but there's a lot of work to be done between selecting a clinical candidate and eventually selling an approved product, and companies have learned that commercial scale manufacturing is a challenge that has to be addressed early on in development.

You may also be interested in...



Tmunity Raises $100m Series A To Fund Next-Gen T-Cell Therapy Trials

Tmunity launched in early 2016 with $10m in seed funding for novel T-cell therapies, two of which are now in the clinic. The company reunites former Novartis cell therapy head Oz Azam and CAR-T researchers from the University of Pennsylvania.

Much Anticipated JULIET Data Show Novartis Playing Catch-Up On CAR-T Manufacturing

Novartis reported positive early results for its lead CAR-T candidate CTL019 in DLBCL that appear to be consistent with Kite's competing therapy in the same indication, but the data show the Swiss big pharma ran into manufacturing issues that weren't resolved until later in the JULIET study.

Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.

Topics

Related Companies

UsernamePublicRestriction

Register

SC030011

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel